New shot combo aims to silence hepatitis b virus
NCT ID NCT07245953
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests two experimental injections, HT-101 and HT-102, in 60 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if the combination can lower hepatitis B virus levels to undetectable and help the immune system control the infection. The trial is double-blind and placebo-controlled, meaning some participants receive dummy shots for comparison.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HT-101 and HT-102 injections
- What this could lead to
- If successful, this combination could offer a new way to control chronic hepatitis B, potentially allowing patients to stop long-term antiviral therapy.
- What could go wrong
- This is an early Phase 2 study with only 60 participants, so results may not apply broadly. The treatment may not work as hoped, and side effects are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Ditan Hospital Capital Medical University
Beijing, Beijing Municipality, 100015, China
-
Guangzhou Eighth People's Hospital, Guangzhou Medical University
Guangzhou, Guangdong, 510440, China
-
Henan Infectious Diseases Hospital , The Sixth People's Hospital of Zhengzhou
Zhengzhou, Henan, 450000, China
-
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, 350028, China
-
Nanchang Ninth Hospital
Nanchang, Jiangxi, 330022, China
-
Nanfang Hospital
Guangzhou, Guangdong, 510515, China
-
Qingyuan People's Hospital
Qingyuan, Guangdong, 511518, China
-
Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine
Nanning, Guangxi, 530011, China
-
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, 200083, China
-
Sichuan Provincial People's Hospital
Chengdu, Sichuan, 610072, China
-
The Second Hospital of Nanjing
Nanjing, Jiangsu, 210003, China
-
Zhenjiang Third People's Hospital (Zhenjiang Infectious Diseases Hospital)
Zhenjiang, Jiangsu, 212021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new shot help control hepatitis d in people with hepatitis b?
- Stick-On ultrasound patch could spot liver damage without a specialist
- New drug combo aims to silence hepatitis b virus
- New DNA test could sharpen hepatitis b monitoring
- 10-Year hepatitis study aims to unlock secrets of liver disease
- Could a short course of antiviral drugs stop hepatitis b passing from mother to child?